Claims

- A method for preparing a conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), the method comprising reacting at least one functional group A of the polymer or the derivative thereof with at least one functional group Z of the protein and thereby forming a covalent linkage, wherein Z is selected from the group consisting of an amino group, a thiol group, an aldehyde group and a keto group, and
 - wherein, in case Z is an aldehyde group or a keto group, A comprises an amino group forming said linkage with Z, or
 - wherein, in case Z is an amino group, A is selected from the group consisting of a reactive carboxy group and an aldehyde group, a keto group or a hemiacetal group,
 - -- wherein, in case A is an aldehyde group, a keto group or a hemiacetal group, the method further comprises introducing A in the polymer to give a polymer derivative
 - --- by reacting the polymer with an at least bifunctional compound, one functional group of which reacts with the polymer and at least one other functional group of which is an aldehyde group, a keto group or a hemiacetal group, or is a functional group which is further chemically modified to give an aldehyde group, a keto group or a hemiacetal group, or
 - --- by oxidizing the polymer to give at least one, in particular at least two aldehyde groups, or
 - -- wherein, in case A is a reactive carboxy group, the method further comprises introducing A in the polymer to give a polymer derivative
 - --- by selectively oxidizing the polymer at its reducing end and activating the resulting carboxy group, or
 - --- by reacting the polymer at its non-oxidized reducing end with a carbonic diester, or
 - wherein, in case Z is a thiol group, A comprises

20

15

25

- -- a maleimido group or
- -- a halogenacetyl group forming said linkage with Z.
- 5 2. The method as claimed in claim 1 wherein the hydroxyalkyl starch is hydroxyethyl starch.
 - 3. The method as claimed in claim 2 wherein the hydroxyethyl starch has a molecular weight of from 2 to 200 kD, preferably of from 4 to 130 kD, more preferably of from 4 to 70 kD.
 - 4. The method as claimed in any of claims 1 to 3, wherein Z is an aldehyde group or a keto group.
- 15 5. The method as claimed in claim 4, wherein the aldehyde group or the keto group is located in a carbohydrate side chain of the protein and/or at the N-terminal group of the protein.
- 6. The method as claimed in claim 5, further comprising oxidizing the carbohydrate side chain of the protein and/or oxidizing the N-terminal group of the protein to give the aldehyde group or keto group.
- 7. The method as claimed in claim 6, wherein the oxidation reaction is carried out enzymatically or using a periodate, in each case, if necessary, after having removed a terminal sialic acid.
 - 8. The method as claimed in any of claims 4 to 7, further comprising reacting the polymer at its non-oxidized reducing end with an at least bifunctional linking compound comprising a functional group capable of reacting with the non-oxidized reducing end of the polymer and a group A, prior to the reaction of the polymer derivative comprising A and the protein comprising Z.
 - 9. The method as claimed in any of claims 4 to 8, wherein A is an aminooxy group or a hydrazido group.

- 10. The method as claimed in claim 8 or 9, wherein the at least bifunctional linking compound is a homobifunctional compound.
- 5 11. The method as claimed in claim 10, wherein the homobifunctional compound comprises two aminooxy groups.
 - 12. The method as claimed in claim 11, wherein the homobifunctional compound is O-[2-(2-aminooxy-ethoxy)-ethyl]hydroxyl amine.
 - 13. The method as claimed in any of claims 8 to 12, wherein the reaction of the polymer with the at least bifunctional linking compound is carried out in an aqueous medium.
- 14. The method as claimed in any of claims 11 to 13, wherein the reaction of the polymer with the at least bifunctional linking compound leads to an oxime linkage and/or an oxyamino linkage.
 - 15. The method as claimed in any of claims 1 to 3, wherein Z is an amino group.
- 20 16. The method as claimed in claim 15, further comprising selectively oxidising the polymer at its reducing end and reacting the oxidised polymer with N,N'-disuccinimidyl carbonate at its oxidised reducing end to give a polymer derivative comprising the reactive carboxy group A.
- 25 17. The method as claimed in claim 15, further comprising reacting at least one hydroxy group of the polymer whose reducing end is not oxidised, with a carbonic diester to give the reactive carboxy group A.
- 18. The method as claimed in claim 17, wherein the carbonic diester is a symmetrical diester.
 - 19. The method as claimed in claim 17 or 18, wherein the alcohol component of the ester is selected from the group consisting of N-hydroxy succinimide, sulfonated N-

20

hydroxy succinimide, N-hydroxy benzotriazole, and nitro- or halogen-substituted phenols.

- 20. The method as claimed in claim 19, wherein the halogen-substituted phenol is selected from the group consisting of nitrophenol, dinitrophenol, trichlorophenol, trifluorophenol, pentachlorophenol, and pentafluorophenol.
- 21. The method as claimed in any of claims 17 to 20, wherein the reaction of the at least one hydroxy group of the polymer whose reducing end is not oxidised, with the carbonic diester to give a reactive ester group A is carried out in an anhydrous aprotic polar solvent.
 - 22. The method as claimed in claim 21, wherein the solvent is dimethyl acetamide, dimethyl formamide or a mixture thereof.
 - 23. The method as claimed in claim 15, wherein A is an aldehyde group, a keto group or a hemiacetal group, the method further comprising reacting the polymer with a functional group M of an at least bifunctional compound to give a polymer derivative, the at least bifunctional compound further comprising at least one other functional group Q which is the aldehyde group, keto group or hemiacetal group A.
 - 24. The method as claimed in claim 23, wherein M comprises an amino group.
- 25. The method as claimed in claim 23, wherein A is an aldehyde group, keto group or hemiacetal group, the method further comprising reacting the polymer with a functional group M of an at least bifunctional compound to give a polymer derivative, the at least bifunctional compound further comprising at least one other functional group Q which is not an aldehyde group, keto group or hemiacetal group, the method further comprising reacting the functional group Q with at least one suitable compound to give the polymer derivative comprising the aldehyde group, keto group or hemiacetal group A.
 - 26. The method as claimed in claim 24, wherein M and Q comprise an amino group.

WO 2005/014050 PCT/EP2004/008818

- 27. The method as claimed in claim 25 or 26, wherein the at least one suitable compound comprises a carboxy group and an aldehyde group, keto group or hemiacetal group.
- 28. The method as claimed in claim 27, wherein the at least one suitable compound is formylbenzoic acid or 4-(4-formyl-3,5-dimethoxyphenoxy)butyric acid.
 - 29. The method as claimed in claim 25 or 26, wherein M comprises an amino group and Q comprises a beta hydroxy amino group.
- 10 30. The method as claimed in claim 29, wherein the polymer is reacted at its oxidized reducing end with a functional group M of an at least bifunctional compound.
 - 31. The method as claimed in claim 29, further comprising oxidizing the beta hydroxyamino group to give the aldehyde group.
 - 32. The method as claimed in claim 31, wherein the oxidation reaction is carried out using a periodate.

15

- 33. The method as claimed in claim 15, wherein the polymer is subjected to a ringopening oxidation reaction using a periodate to give a polymer derivative having at least one, in particular at least two aldehyde groups A.
 - 34. The method as claimed in any of claims 23 to 33, wherein the reaction of the polymer or the polymer derivative with the protein is a reductive amination.
 - 35. The method as claimed in claim 34, wherein the reductive amination is carried out in the presence of NaCNBH₃.
- 36. The method as claimed in claim 34 or 35, wherein the reductive amination is carried out at a pH of 7 or less.
 - 37. The method as claimed in claim 36, wherein the pH is 6 or less.

- 38. The method as claimed in any of claims 34 to 37, wherein the reductive amination is carried out at a temperature of from 0 to 25 °C.
- 39. The method as claimed in any of claims 34 to 38, wherein the reductive amination is carried out in an aqueous medium.
 - 40. The method as claimed in any of claims 1 to 3, wherein Z is a thiol group.
- 41. The method as claimed in claim 40, wherein A comprises a halogenacetyl group, the
 method further comprising reacting the polymer at its optionally oxidized reducing
 end with an at least bifunctional compound having at least two functional groups
 each comprising an amino group to give a polymer derivative having at least one
 functional group comprising an amino group, the method further comprising reacting
 the polymer derivative with a monohalogen-substituted acetic acid and/or a reactive
 monohalogen-substituted acetic acid derivative.
 - 42. The method as claimed in claim 41, wherein the halogen is Br or I.
- 43. The method as claimed in claim 41 or 42, wherein the at least bifunctional compound is a diaminoalkane having from 2 to 10 carbon atoms.
 - 44. The method as claimed in claim 41 or 42, wherein the at least bifunctional compound is a diaminopolyethylene glycol having from 1 to 5 alkylene units.
- 25 45. The method as claimed in any of claims 41 to 44, wherein the polymer is reacted with the at least bifunctional compound at its oxidized reducing end.
- 46. The method as claimed in any of claims 41 to 45, wherein the polymer derivative comprising the halogenacetyl group is reacted with the protein in the presence of a solvent comprising a mixture of dimethyl formamide and water.
 - 47. The method as claimed in claim 40, wherein A comprises a maleimido group, the method further comprising reacting the polymer at its optionally oxidized reducing end with an at least bifunctional compound comprising a functional group U capable

of reacting with the optionally oxidised reducing end, the at least bifunctional compound further comprising a functional group W capable of being chemically modified to give a maleimido group, the method further comprising chemically modifying the functional group W to give a maleimido group.

- 5
- 48. The method as claimed in claim 47, wherein U comprises an amino group.
- 49. The method as claimed in claim 47 or 48, wherein W comprises an amino group.
- 10 50. The method as claimed in any of claims 47 to 49, wherein the polymer derivative comprising W is reacted with an at least bifunctional compound comprising a functional group capable of being reacted with W and further comprising a maleimido group.
- 15 51. The method as claimed in claim 50, wherein the at least bifunctional compound is N-(alpha-maleimidoacetoxy)succinimide ester.
 - 52. A conjugate as obtainable by a method as claimed in any of claims 1 to 51.
- 20 53. The conjugate as claimed in claim 52, wherein A is a reactive carboxy group, and wherein A was introduced in the polymer whose reducing end was not oxidized, by reacting at least one hydroxy group of the polymer with a carbonic diester, and wherein, said comprising one polymer molecule and at least one, in particular of from 1 to 10 protein molecules linked to the polymer via amide linkages.
- 25
- 54. A conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

and/or

wherein R₁, R₂ and R₃ are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group,

wherein G is selected from the group consisting of O and S, preferably O, and wherein L is an optionally suitably substituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom, preferably an alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl residue having from 2 to 60 carbon atoms.

- 55. The conjugates as claimed in claim 54, wherein -L- is -(CH₂)n- with n = 2, 3, 4, 5, 6, 7, 8, 9, 10, preferably 2, 3, 4, 5, 6, more preferably 2, 3, 4, and especially preferably 4.
- 56. A conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

20

5

10

15

and/or

10

15

wherein R₁, R₂ and R₃ are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group, and wherein G is selected from the group consisting of O and S, preferably O.

57. A conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

and/or

wherein R₁, R₂ and R₃ are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 1 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group, and wherein L is an optionally suitably substituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom, preferably an

alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl residue having from 2 to 60 carbon atoms.

58. The conjugate as claimed in claim 57, wherein -L- is

 $-[(CR_aR_b)_mG]_n[CR_cR_d]_o$

wherein R_a; R_b, R_c, R_d are independently hydrogen, alkyl, aryl, preferably hydrogen, wherein G is selected from the group consisting of O and S, preferably O, and wherein

- m 1, 2, 3 or 4, wherein the residues R_a and R_b may be the same or different in the m groups (CR_aR_b);
- n 0 to 20, preferably 0 to 10, more preferably 1, 2, 3, 4, 5, most preferably 1 or 2;
- o 0 to 20, preferably 0 to 10, more preferably 1, 2, 3, 4, 5, most preferably 1 or 2, wherein the residues R_c and R_d may be the same or different in the o groups (CR_cR_d);

15

25

30

5

- 59. The conjugate as claimed in claim 57 or 58, wherein R_a ; R_b , R_c , R_d are hydrogen, m = 2, n = 1, and o = 2.
- 60. A conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

wherein R₁, R₂ and R₃ are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group.

61. A conjugate comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

wherein R₁, R₂ and R₃ are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group, and

wherein the linkage -O-(C=O)- was formed by a reaction of a carboxy group or a reactive carboxy group with a hydroxy group of the HAS molecule, and wherein HAS" refers to the HAS molecule without said hydroxy group.

10 62. A conjugate, comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

HAS'
$$OR_1$$
 H OR_3 OR_2 H OR_3 OR_4 H OR_4 OR_5 OR_5 OR_5 OR_6 OR_6

and/or

HAS'
$$R_{2}O$$

$$H$$

$$OR_{3}$$

$$OR_{4}$$

$$OR_{3}$$

$$OR_{3}$$

$$OR_{4}$$

$$OR_{3}$$

$$OR_{4}$$

$$OR_{5}$$

$$OR_{5}$$

$$OR_{6}$$

$$OR_{7}$$

$$OR_{7}$$

$$OR_{8}$$

$$OR_{8}$$

15

wherein R_1 , R_2 and R_3 are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group, and

20

wherein L is an optionally substituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom, having from 1 to 60 preferably from 1 to 40, more preferably from 1 to 20, more preferably from 1 to 10,

15

25

more preferably from 1 to 6 more preferably from 1 to 2 carbon atoms and especially preferably 1 carbon atom, L being in particular CH₂.

63. A conjugate, comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

HAS'
$$R_{2}O$$

$$H$$

$$OR_{3}$$

$$OR_{2}$$

$$OR_{3}$$

$$OR_{3}$$

$$OR_{3}$$

$$OR_{3}$$

$$OR_{3}$$

$$OR_{4}$$

$$OR_{4}$$

$$OR_{4}$$

$$OR_{5}$$

$$O$$

wherein R_1 , R_2 and R_3 are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group, and

wherein L_1 and L_2 are independently an optionally substituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom, comprising an alkyl, aryl, aralkyl heteroalkyl, and/or heteroaralkyl moiety, said residue having from 1 to 60 preferably from 1 to 40, more preferably from 1 to 20, more preferably from 1 to 10 carbon atoms, and

wherein D is a linkage, preferably a covalent linkage which was formed by a suitable functional group F_2 linked to L_1 and a suitable functional group F_3 linked to L_2 .

- 20 64. The conjugate as claimed in claim 63, wherein L₁ is -(CH₂)n- with n = 2, 3, 4, 5, 6, 7, 8, 9, 10, preferably 2, 3, 4, 5, 6, more preferably 2, 3, 4, and especially preferably 4.
 - 65. The conjugate as claimed in claim 63 or 64, wherein L₂ comprises an optionally suitably substituted aryl moiety, preferably an aryl moiety containing 6 carbon atoms, L₂ being especially preferably C₆H₄.
 - 66. The conjugate as claimed in any of claims 63 to 65, wherein is F₂ selected from the group consisting of
 - C-C-double bonds or C-C-triple bonds or aromatic C-C-bonds;

- the thiol group or the hydroxy groups;
- alkyl sulfonic acid hydrazide, aryl sulfonic acid hydrazide;
- 1,2-dioles;
- 1,2 amino-thioalcohols;
- 5 azides;

20

25

30

- 1,2-aminoalcohols;
- the amino group -NH₂ or derivatives of the amino groups comprising the structure unit -NH- such as aminoalkyl groups, aminoaryl group, aminoaralkyl groups, or alkarlyaminogroups;
- the hydroxylamino group -O-NH₂, or derivatives of the hydroxylamino group comprising the structure unit -O-NH-, such as hydroxylalkylamino groups, hydroxylarylamino groups, hydroxylaralkylamino groups, or hydroxalalkarylamino groups;
 - alkoxyamino groups, aryloxyamino groups, aralkyloxyamino groups, or alkaryloxyamino groups, each comprising the structure unit -NH-O-;
 - residues having a carbonyl group, -Q-C(=G)-M, wherein G is O or S, and M is, for example,
 - -- -OH or -SH;
 - -- an alkoxy group, an aryloxy group, an aralkyloxy group, or an alkaryloxy group;
 - an alkylthio group, an arylthio group, an aralkylthio group, or an alkarylthio group;
 - -- an alkylcarbonyloxy group, an arylcarbonyloxy group, an aralkylcarbonyloxy group, an alkarylcarbonyloxy group;
 - -- activated esters such as esters of hydroxylamines having imid structure such as N-hydroxysuccinimide or having a structure unit O-N where N is part of a heteroaryl compound or, with G = O and Q absent, such as aryloxy compounds with a substituted aryl residue such as pentafluorophenyl, paranitrophenyl or trichlorophenyl;

wherein Q is absent or NH or a heteroatom such as S or O;

- NH-NH₂, or -NH-NH-;
- -NO₂;
- the nitril group;
- carbonyl groups such as the aldehyde group or the keto group;

- the carboxy group;
- the -N=C=O group or the -N=C=S group;
- vinyl halide groups such as the vinyl iodide or the vinyl bromide group or triflate;
- 5 -C≡C-H;
 - -(C=NH₂Cl)-OAlkyl
 - groups -(C=O)-CH₂-Hal wherein Hal is Cl, Br, or I;
 - -CH=CH-SO₂-;
 - a disulfide group comprising the structure -S-S-;

the group
$$O_2N$$

and wherein F₃ is a functional group capable of forming a chemical linkage with F₂ and is preferably selected from the above-mentioned group, F₂ preferably comprising the moiety -NH-, more preferably comprising an amino group, F₃ preferably comprising the moiety -(C=G)-, more preferably -(C=O)-, more preferably the moiety -(C=G)-G-, still more preferably -(C=O)-G-, and especially preferably -(C=O)-O, D being particularly preferably an amide linkage.

67. A conjugate, comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

20

10

15

wherein the carbon atom of the moiety -CH₂-N2- is derived from an aldehyde group which was introduced in the polymer by a ring-opening oxidation reaction, and wherein the nitrogen atom is derived from an amino group of the protein.

68. A conjugate, comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

5

wherein R₁, R₂ and R₃ are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group, and

wherein L is an optionally substituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom, comprising an alkyl, aryl, aralkyl heteroalkyl, and/or heteroaralkyl moiety, said residue having from 2 to 60 preferably from 2 to 40, more preferably from 2 to 20, more preferably from 2 to 10 carbon atoms, and

wherein the sulfur atom is derived from a cysteine residue or a disulfide group of the protein.

69. The conjugate as claimed in claim 68, wherein -L- is

$$-[(CR_aR_b)_mG]_n[CR_cR_d]_o-$$

- wherein R_a; R_b, R_c, R_d are independently hydrogen, alkyl, aryl, preferably hydrogen, wherein G is selected from the group consisting of O and S, preferably O, and wherein
 - m 1, 2, 3 or 4, most preferably 2, wherein the residues R_a and R_b may be the same or different in the m groups (CR_aR_b);

n 1 to 20, preferably 1 to 10, most preferably 1, 2, 3, or 4;

o 1 to 20, preferably 1 to 10, more preferably 1, 2, 3, 4, 5, more preferably 1 or 2, most preferably 1, wherein the residues R_c and R_d may be the same or different in the o groups (CR_cR_d);

or

30 wherein

20

25

- n 0, and
- o 2 to 20, preferably 2 to 10, more preferably 2, 3, 4, 5, 6, 7, or 8, wherein the residues R_c and R_d may be the same or different in the 0 groups CR_cR_d .
- 5 70. A conjugate, comprising a protein and a polymer or a derivative thereof, wherein the polymer is a hydroxyalkyl starch (HAS) and the protein is a granulocyte colony stimulating factor (G-CSF), having a structure according to the formula

wherein R₁, R₂ and R₃ are independently hydrogen or a hydroxyalkyl group, a hydroxyaryl group, a hydroxyaralkyl group or a hydroxyalkaryl group having of from 2 to 10 carbon atoms, preferably hydrogen or a hydroxyalkyl group, more preferably hydrogen or a hydroxyethyl group, and

wherein L is an optionally substituted, linear, branched and/or cyclic hydrocarbon residue, optionally comprising at least one heteroatom, comprising an alkyl, aryl, aralkyl heteroalkyl, and/or heteroaralkyl moiety, said residue having from 2 to 60 preferably from 2 to 40, more preferably from 2 to 20, more preferably from 2 to 10 carbon atoms, and

wherein the sulfur atom is derived from a cysteine residue or a disulfide group of the protein.

71. The conjugate as claimed in claim 70, wherein -L- is

$$-[(CR_aR_b)_mG]_n[CR_cR_d]_0$$
-

wherein R_a; R_b, R_c, R_d are independently hydrogen, alkyl, aryl, preferably hydrogen, wherein G is selected from the group consisting of O and S, preferably O, and wherein

- m 1, 2, 3 or 4, most preferably 2, wherein the residues R_a and R_b may be the same or different in the m groups C R_a R_b;
- n 1 to 20, preferably 1 to 10, most preferably 1, 2, 3, or 4;

1 to 20, preferably 1 to 10, more preferably 1, 2, 3, 4, 5, more preferably 1 or 2, most preferably 1, wherein the residues R_c and R_d may be the same or different in the 0 groups CR_cR_d;

or

wherein

15

- n 0, and
- 2 to 20, preferably 2 to 10, more preferably 2, 3, 4, 5, 6, 7, or 8, wherein the residues R_c and R_d may be the same or different in the 0 groups CR_cR_d.
- 10 72. The conjugate as claimed in any of claims 54 to 71, wherein the hydroxyalkyl starch is hydroxyethyl starch.
 - 73. The conjugate as claimed in claim 72 wherein the hydroxyethyl starch has a molecular weight of from 2 to 200 kD, preferably of from 4 to 130 kD, more preferably of from 4 to 70 kD.
 - 74. A conjugate as claimed in any of claims 52 to 73, for use in a method for the treatment of the human or animal body.
- 75. A pharmaceutical composition comprising in a therapeutically effective amount a conjugate as claimed in any of claims 52 to 73.
 - 76. A pharmaceutical composition as claimed in claim 75, further comprising at least one pharmaceutically acceptable diluent, adjuvant, or carrier.
 - 77. Use of a conjugate as claimed in any of claims 52 to 73 for the preparation of a medicament for the treatment of a disorder characterized by a reduced hematopoietic or immune function.
- 78. The use as claimed in claim 77, wherein the disorder is a result of chemotherapy, radiation therapy, infectious disease, severe chronic neutropenia, or leukemia.